Twist Bioscience (NASDAQ:TWST) CEO Emily Leproust Sells 18,880 Shares

Twist Bioscience Corporation (NASDAQ:TWST) CEO Emily Leproust sold 18,880 shares of the stock in a transaction dated Thursday, June 25th. The stock was sold at an average price of $95.00, for a total value of $1,793,600.00. Following the completion of the sale, the chief executive officer owned 824,039 shares of the company’s stock, valued at $78,283,705. This trade represents a 2.24% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Twist Bioscience Trading Up 3.3%

NASDAQ TWST opened at $99.84 on Friday. The company has a debt-to-equity ratio of 0.03, a current ratio of 2.70 and a quick ratio of 2.42. The stock’s 50-day moving average is $67.01 and its 200-day moving average is $51.44. Twist Bioscience Corporation has a one year low of $23.30 and a one year high of $104.23. The firm has a market cap of $6.22 billion, a P/E ratio of -75.07 and a beta of 2.23.

Twist Bioscience (NASDAQ:TWST) last announced its earnings results on Monday, May 4th. The company reported ($0.71) EPS for the quarter, missing the consensus estimate of ($0.49) by ($0.22). Twist Bioscience had a negative return on equity of 26.73% and a negative net margin of 19.85%.The company had revenue of $110.72 million for the quarter, compared to analyst estimates of $107.64 million. During the same quarter last year, the business posted ($0.66) earnings per share. The business’s quarterly revenue was up 19.3% on a year-over-year basis. Sell-side analysts anticipate that Twist Bioscience Corporation will post -2.02 earnings per share for the current fiscal year.

Institutional Trading of Twist Bioscience

Institutional investors have recently made changes to their positions in the business. Quarry LP acquired a new position in Twist Bioscience during the third quarter worth $28,000. Western Wealth Management LLC acquired a new stake in Twist Bioscience in the 1st quarter valued at $31,000. Strs Ohio bought a new stake in Twist Bioscience during the 1st quarter worth about $33,000. Strategic Advocates LLC lifted its position in Twist Bioscience by 562.7% during the 4th quarter. Strategic Advocates LLC now owns 1,067 shares of the company’s stock worth $34,000 after buying an additional 906 shares in the last quarter. Finally, SBI Securities Co. Ltd. boosted its stake in shares of Twist Bioscience by 68.9% during the 4th quarter. SBI Securities Co. Ltd. now owns 1,400 shares of the company’s stock worth $44,000 after buying an additional 571 shares during the last quarter.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on the stock. Robert W. Baird raised their price objective on shares of Twist Bioscience from $50.00 to $65.00 and gave the stock an “outperform” rating in a report on Tuesday, May 5th. Canaccord Genuity Group initiated coverage on shares of Twist Bioscience in a research note on Monday, June 15th. They issued a “buy” rating and a $90.00 target price for the company. Barclays increased their target price on Twist Bioscience from $65.00 to $95.00 and gave the stock an “overweight” rating in a report on Wednesday. Leerink Partners set a $80.00 price target on Twist Bioscience in a report on Friday, May 22nd. Finally, TD Cowen upped their price objective on Twist Bioscience from $68.00 to $89.00 and gave the stock a “buy” rating in a research report on Monday, June 15th. Nine analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $74.60.

Twist Bioscience Company Profile

Twist Bioscience Corporation is a synthetic biology company specializing in the development and commercialization of DNA-based products and solutions. Founded in 2013 and headquartered in South San Francisco, California, the company has pioneered a proprietary silicon-based DNA synthesis platform designed for high-throughput production of synthetic genes and oligonucleotides. Twist leverages semiconductor manufacturing techniques to enable precise, scalable synthesis of DNA at speeds and volumes unattainable with traditional methods.

At the core of Twist’s offering is its proprietary platform that automates the synthesis of custom DNA fragments, gene libraries, and long oligonucleotides.